血管內皮生長因子B(VEGFB)重組蛋白
Recombinant Vascular Endothelial Growth Factor B (VEGFB)
VEGF-B; VEGFL; VRF; VEGF-Related Factor
- 編號RPA144Mu02
- 物種Mus musculus (Mouse,小鼠) 相同的名稱,不同的物種。
- 來源原核表達
- 宿主E.coli
- 內毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位n/a
- 預測分子量-
- 實際分子量-(差異分析請參閱說明書)
- 片段與標簽N-terminal His Tag
- 緩沖液成份磷酸鹽緩沖液(pH7.4,含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.)
- 性狀凍干粉
- 純度> 97%
- 等電點-
-
應用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1003 ¥ 2508 ¥ 5016 ¥ 15048 ¥ 37620
- 欲了解實際交易價格和更多情況,請與當地經銷商聯(lián)系!
序列
用法
PBS或其它。
儲存
避免反復凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產生。保質期內,在適當的條件下存儲,損失率低于5%。
增值服務
相關產品
編號 | 適用物種:Mus musculus (Mouse,小鼠) | 應用(僅供研究使用,不用于臨床診斷!) |
RPA144Mu01 | 血管內皮生長因子B(VEGFB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA144Mu02 | 血管內皮生長因子B(VEGFB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA144Mu01 | 血管內皮生長因子B(VEGFB)多克隆抗體 | WB; IHC; ICC; IP. |
PAA144Mu02 | 血管內皮生長因子B(VEGFB)多克隆抗體 | WB; IHC; ICC; IP. |
SEA144Mu | 血管內皮生長因子B(VEGFB)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
MEA144Mu | 血管內皮生長因子B(VEGFB)檢測試劑盒(酶聯(lián)免疫吸附試驗法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA144Mu | 血管內皮生長因子B(VEGFB)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
雜志 | 參考文獻 |
International Journal of Cardiology | Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. [PubMed: 22459379] |
Applied Sciences-Basel | Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study [pubmed:29099033] |
Journal of Endocrinological Investigation | Plasma vascular endothelial growth factor B levels are increased in patients with newly diagnosed type 2 diabetes mellitus and associated with the first phase of glucose-stimulated insulin secretion function of β-cell [10.1007/s40618-017-0677-z] |
EXCLI Journal | Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction [] |
Cancer Chemother Pharmacol | Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors [34164713] |
留言咨詢